← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sequella, Inc.
Rockville, MD
$21,124,256
Total funding
30
Grants
Funding over time
peak $2.1M · FY2005–15$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$21,124,256 · 30
By mechanism
R44$5,497,036 · 3
R43$4,424,863 · 13
R01$3,716,788 · 1
UC1$2,575,653 · 2
R21$1,968,963 · 3
U01$1,894,528 · 1
Investigators at Sequella, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Advancing a new TB drug through early clinical trials$1,361,370
UC1 · FY2004 · AI
Second Generation Antibiotics from Ethambutol$1,214,283
UC1 · FY2000 · AI
A Rapid Lateral Flow Test for TB in Nonhuman Primates$986,376
R44 · FY2003 · RR
A Rapid Lateral Flow Test for TB in Nonhuman Primates$986,376
R44 · FY2004 · RR
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs$850,410
R44 · FY2010 · AI
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection$806,416
R01 · FY2012 · AI
Commercial Development of the Bronx Box$802,717
R44 · FY2002 · AI
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs$795,701
R44 · FY2009 · AI
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs$793,901
R44 · FY2008 · AI
A Second-Generation Patch Test for Tuberculosis$736,439
U01 · FY2005 · AI
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection$730,895
R01 · FY2011 · AI
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection$728,339
R01 · FY2015 · AI
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection$725,821
R01 · FY2013 · AI
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection$725,317
R01 · FY2014 · AI
Investigation of synergy between Rifampin and SQ109, a new anti-TB drug candidate$693,529
R21 · FY2009 · AI
A Second-Generation Patch Test for Tuberculosis$621,250
U01 · FY2004 · AI
Clinical Development of SQ109 for H. pylori Infection$313,110
R21 · FY2012 · DK
Advancing lead dipiperidine compound into preclinical development$305,054
R43 · FY2009 · AI
ELECTRONIC MONITORING OF COMPLIANCE WITH TB CHEMOTHERAPY$300,000
R43 · FY2000 · AI
SQ641, new drug candidate to treat NTM infections$300,000
R43 · FY2010 · AI